Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1045-1052

  Lewandowska, Marzena Anna ^a,b   Jozwicki, Wojciech ^a,b   Jochymski, Cezary ^a   Kowalewski, Janusz ^a,b  

^a Regional Oncology Centre Bydgoszcz   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

BRAF; EGFR; KRAS; Molecular cytopathology; Molecular diagnostics; Personalized medicine

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ARTICLE; BRAF GENE; BRONCHUS BIOPSY; CYTOLOGY; EGFR GENE; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSBRONCHIAL ASPIRATION; TUMOR CELL;

ADENOCARCINOMA; BIOPSY; BIOPSY, FINE-NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84880604870     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2579     Document Type: Article

References (31)

1. Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M and Cognetti F: EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J Thorac Oncol 7: 672-680, 2012.
2. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J and Shepherd FA: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Eng J Med 353: 133-144, 2005.
3. Malapelle U, Bellevicine C, Zeppa P, Palombini L and Troncone G: Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. Diagn Cytopathol 39: 703-710, 2011.
4. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH and Pao W: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
5. Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA and Pao W: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 14: 7519-7525, 2008.
6. Wu SG, Shih JY, Yu CJ and Yang PC: Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. J Thorac Oncol 3: 451-452, 2008.
7. Garcia-Olivé I, Monsó E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjós M, Castellà E, Moran T, Bertran-Alamillo J, Mayo-de-Las-Casas C, Queralt C and Rosell R: Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 35: 391-395, 2010.
8. Lewandowska MA, Jóźwicki W, Starzynski J and Kowalewski J: Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: may a clinical and pathological model of a patient's qualification for targeted therapy have an impact on time to obtain genetic results? Pol J Cardiothorac Surg 9: 443-451, 2012
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med 350: 2129-2139, 2004.
10. Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, Abe H, Yamaguchi T, Takamori S, Akiba J and Kage M: Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 74: 35-40, 2011.
11. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM: Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15: 2076-2084, 2009.
12. Marotti JD, Schwab MC, McNulty NJ, Rigas JR, Delong PA, Memoli VA, Tsongalis GJ and Padmanabhan V: Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases. Diagn Cytopathol 41: 15-21, 2013.
13. Dacic S, Shuai Y, Yousem S, Ohori P and Nikiforova M: Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23: 159-168, 2010.
14. Pennycuick A, Simpson T, Crawley D, Lal R, Santis G, Cane P, Tobal K and Spicer J: Routine EGFR and KRAS mutation analysis using COLD-PCR in non-small cell lung cancer. Int J Clin Pract 66: 748-752, 2012.
15. Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel- Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, Thunnissen FB, Heideman DA, de Weger RA and Vink A: EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol 35: 189-196, 2012.
16. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, Dobrovic A and Iacopetta B: A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 11: 543-552, 2009.
17. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH and Lindeman NI: EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 117: 67-72, 2009.
18. Nomoto K, Tsuta K, Takano T, Fukui T, Yokozawa K, Sakamoto H, Yoshida T, Maeshima AM, Shibata T, Furuta K, Ohe Y and Matsuno Y: Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126: 608-615, 2006.
19. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17, 2005.
20. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
21. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR and Meyerson M: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313, 2005.
22. Stamos J, Sliwkowski MX and Eigenbrot C: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277: 46265-46272, 2002.
23. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M and Eck MJ: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227, 2007.
24. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J and Haber DA: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670, 2005.
25. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Eng J Med 352: 786-792, 2005.
26. Lin WH, Song JS, Lien TW, Chang CY, Wu SH, Huang YW, Chang TY, Fang MY, Yen KJ, Chen CH, Chu CY, Hsieh HP, Chen YR, Chao YS and Hsu JT: A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors. Anticancer Res 32: 147-151, 2012.
27. Taube E, Jokinen E, Koivunen P and Koivunen JP: A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. Int J Cancer 131: 970-979, 2012.
28. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H and Wong KK: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711, 2008.
29. Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K and O'Byrne K: The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol 65: 1-7, 2012.
30. Lewandowska MA, Jóźwicki W and Zurawski B: KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther 17: 193-203, 2013.
31. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JKC, Grigioni WF, Campo E, Pileri SA and Falini B: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174: 661-670, 2009.